Synt:em was founded by Michel Kaczorek and Caroline Roussel in 1995. Synt:em has a balanced business model, based on its unique Pep:trans(TM) and Acti:map(TM) technology platforms which allow it to develop New Chemical Entities (NCEs) as well as to deliver compounds to the brain or other intracellular targets. Synt:em's strategy is based on developing a pipeline of drug candidates in the field of CNS diseases through its own internal R&D programmes. In the short term Synt:em intends to use its Pep:trans(TM) technology to enhance the efficacy of any type of bioactive compound targeting the brain; in the long term, completely novel NCEs will be designed from its Acti:map(TM) technology and developed. Synt:em aim to enter collaborations with international pharmaceutical and biotechnology companies to develop new compounds in different therapeutic fields, such as vaccination, inflammation, immunosuppression and oncology.